UBI Ubisoft Entertainment SA

UBISOFT ANNOUNCES DEPARTURES AND REAFFIRMS ITS COMMITMENT TO IMPLEMENTING SIGNIFICANT CHANGE IN ITS WORKPLACE CULTURE

UBISOFT ANNOUNCES DEPARTURES AND REAFFIRMS ITS COMMITMENT TO IMPLEMENTING SIGNIFICANT CHANGE IN ITS WORKPLACE CULTURE

UBISOFT ANNOUNCES DEPARTURES AND REAFFIRMS ITS COMMITMENT

TO IMPLEMENTING SIGNIFICANT CHANGE IN ITS WORKPLACE CULTURE

Paris – July 12, 2020 – Today, Ubisoft announced several significant personnel changes that are a part of the comprehensive work the Company is doing to improve and strengthen its workplace culture. These departures come following the initiation of a rigorous review that the Company initiated in response to recent allegations and accusations of misconduct and inappropriate behavior.

Serge Hascoët has chosen to resign from his position as Chief Creative Officer, effective immediately. This role will be taken by Yves Guillemot, CEO and Co-Founder of Ubisoft, in the interim. During this time, Mr. Guillemot will personally oversee a complete overhaul of the way in which the creative teams collaborate.

Yannis Mallat, Managing Director of Ubisoft’s Canadian studios, will be stepping down from his role and will leave the Company, effective immediately. The recent allegations that have come to light in Canada against multiple employees make it impossible for him to continue in this position.

Additionally, Ubisoft will be appointing a new Global Head of HR to replace Cécile Cornet, who has decided to step down from this role, as she believes it is in the best interest of the Company’s unity. A search for her replacement will begin immediately, led by an industry-leading recruiting firm. In parallel, the Company is restructuring and strengthening its HR function in order to adapt it to the new challenges of the video game industry. Ubisoft is in the final steps of hiring a top international management consulting firm to audit and reshape its HR procedures and policies, as previously announced. 

These changes are part of a comprehensive set of initiatives announced to employees on July 2, 2020. These initiatives are guiding Ubisoft’s renewed commitment to fostering an environment that its employees, partners and communities can be proud of – one that reflects Ubisoft’s values and that is safe for everyone.

Ubisoft has fallen short in its obligation to guarantee a safe and inclusive workplace environment for its employees. This is unacceptable, as toxic behaviors are in direct contrast to values on which I have never compromised — and never will. I am committed to implementing profound changes across the Company to improve and strengthen our workplace culture,” said Yves Guillemot, CEO and Co-Founder of Ubisoft. “Moving forward, as we collectively embark on a path leading to a better Ubisoft, it is my expectation that leaders across the Company manage their teams with the utmost respect. I also expect them to work to drive the change we need, always thinking of what is best for Ubisoft and all its employees.”

Contacts

Investor Relations

Jean-Benoît Roquette

SVP Investor Relations

39

Press Relations

Michael Burk

Senior Director of Corporate Public Relations

03

 



Alexandre Enjalbert

Senior Investor Relations Manager

78

 

About Ubisoft

Ubisoft is a leading creator, publisher and distributor of interactive entertainment and services, with a rich portfolio of world-renowned brands, including Assassin’s Creed, Far Cry, For Honor, Just Dance, Watch_Dogs, Tom Clancy’s video game series including Ghost Recon, Rainbow Six and The Division. The teams throughout Ubisoft’s worldwide network of studios and business offices are committed to delivering original and memorable gaming experiences across all popular platforms, including consoles, mobile phones, tablets and PCs. For the 2019-20 fiscal year, Ubisoft generated net bookings of €1,534 million. To learn more, please visit:

© 2020 Ubisoft Entertainment. All Rights Reserved. Ubisoft and the Ubisoft logo are registered trademarks in the US and/or other countries.

Attachment

EN
11/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ubisoft Entertainment SA

 PRESS RELEASE

Ubisoft Reports Full-Year 2024-25 Earnings Figures

Ubisoft Reports Full-Year 2024-25 Earnings Figures UBISOFT REPORTS FULL-YEAR 2024-25 EARNINGS FIGURES Assassin’s Creed® Shadows release prompted very strong praise from players and delivered a solid performance, clearly ahead of Assassin’s Creed® Odyssey, highlighting the strength of the brand. FY2024-25 performance broadly in line with targets, FCF at €128m: Net bookings: €1.85bn, slightly below objective, mainly reflecting lower than expected partnerships, notably due to a timing impactNon-IFRS operating income in line with guidance Free Cash Flow ahead of target driven by cash flow ...

 PRESS RELEASE

Ubisoft annonce ses résultats pour l’exercice 2024-25

Ubisoft annonce ses résultats pour l’exercice 2024-25 UBISOFT ANNONCE SES RÉSULTATS POUR L’EXERCICE 2024-25 Le lancement d’Assassin’s Creed® Shadows a suscité des retours très positifs de la part des joueurs et a enregistré une performance solide, nettement supérieure à celle d’Assassin’s Creed Odyssey, illustrant la force de la marque. Performance de l’exercice 2024-25 globalement en ligne avec les objectifs Net bookings : 1,85 Mds€, légèrement en dessous de l’objectif, principalement en raison de partenariats inférieurs aux attentes, notamment lié à un impact de timingRésultat opér...

 PRESS RELEASE

Informations sur les droits de vote et les actions au 30 avril 2025

Informations sur les droits de vote et les actions au 30 avril 2025 Le 9 mai 2025 Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social   Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation :        Euronext ParisCompartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                 Date Nombre total d’actions composant le capital social Nombre total de droits de vote Total brut (1) Total net (2) 30/04/2025 130 848 866 143 648 674 143 648 674         Le nom...

Alicia Reese ... (+4)
  • Alicia Reese
  • Kade Barr
  • Matthew McCartney
  • Michael Pachter
Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
WELL WELLTOWER INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
VTR VENTAS INC.
ISR ISORAY
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
DELL DELL TECHNOLOGIES INC CLASS C
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ITOS KEROS THERAPEUTICS
ZNTL ITEOS THERAPEUTICS
LRMR ZENTALIS PHARMACEUTICALS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
VRDN TRAVERE THERAPEUTICS INC
DAWN VIRIDIAN THERAPEUTICS INC
ELEV DAY ONE BIOPHARMACEUTICALS INC
MRVL ELEVATION ONCOLOGY
STX MARVELL TECHNOLOGY INC
APP SEAGATE TECHNOLOGY HLDGS PLC
ATXS APPLOVIN CORP
GFS ASTRIA THERAPEUTICS INC
GMTX GLOBALFOUNDRIES INC
VIGL GEMINI THERAPEUTICS INC
TYRA VIGIL NEUROSCIENCE INC
EWTX TYRA BIOSCIENCES INC
DDI EDGEWISE THERAPEUTICS INC
APGE DOUBLEDOWN INTERACTIVE CO LTD
SKLZ APOGEE THERAPEUTICS INC
EMBRAC B SKILLZ INC
MXL-US EMBRACER GROUP AB
MAXLINEAR
INC.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch